Literature DB >> 35201435

Anal squamous cell carcinoma in a high HIV prevalence population.

Danielle R L Brogden1,2, Christopher C Khoo1, Christos Kontovounisios3,4, Gianluca Pellino5,6, Irene Chong7,8, Diana Tait7,8, Oliver J Warren1,2, Mark Bower1,2, Paris Tekkis1,2,7, Sarah C Mills1,2.   

Abstract

Anal Squamous Cell Carcinoma (ASCC) is a rare cancer that has a rapidly increasing incidence in areas with highly developed economies. ASCC is strongly associated with HIV and there appears to be increasing numbers of younger male persons living with HIV (PLWH) diagnosed with ASCC. This is a retrospective cohort study of HIV positive and HIV negative patients diagnosed with primary ASCC between January 2000 and January 2020 in a demographic group with high prevalence rates of HIV. One Hundred and seventy six patients were included, and clinical data was retrieved from multiple, prospective databases. A clinical subgroup was identified in this cohort of younger HIV positive males who were more likely to have had a prior diagnosis of Anal Intraepithelial Neoplasia (AIN). Gender and HIV status had no effect on staging or disease-free survival. PLWH were more likely to develop a recurrence (p < 0.000) but had a longer time to recurrence than HIV negative patients, however this was not statistically significant (46.1 months vs. 17.5 months; p = 0.077). Patients known to have a previous diagnosis of AIN were more likely to have earlier staging and local tumour excision. Five-year Disease-Free Survival was associated with tumour size and the absence of nodal or metastatic disease (p < 0.000).
© 2021. The Author(s).

Entities:  

Keywords:  Anal squamous cell carcinoma; Chemoradiotherapy; HIV

Year:  2021        PMID: 35201435     DOI: 10.1007/s12672-021-00397-7

Source DB:  PubMed          Journal:  Discov Oncol        ISSN: 2730-6011


  17 in total

1.  Guidelines for management of anal intraepithelial neoplasia.

Authors:  J H Scholefield; D Harris; A Radcliffe
Journal:  Colorectal Dis       Date:  2011-02       Impact factor: 3.788

2.  Association of Coloproctology of Great Britain & Ireland (ACPGBI): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) - Anal Cancer.

Authors:  Ian Geh; Simon Gollins; Andrew Renehan; John Scholefield; Vicky Goh; Davide Prezzi; Brendan Moran; Mark Bower; Maryam Alfa-Wali; Richard Adams
Journal:  Colorectal Dis       Date:  2017-07       Impact factor: 3.788

3.  The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for Anal Squamous Cell Cancers (Revised 2018).

Authors:  David B Stewart; Wolfgang B Gaertner; Sean C Glasgow; Daniel O Herzig; Daniel Feingold; Scott R Steele
Journal:  Dis Colon Rectum       Date:  2018-07       Impact factor: 4.585

4.  Improving outcomes for the treatment of Anal Squamous Cell Carcinoma and Anal Intraepithelial Neoplasia.

Authors:  D R L Brogden; C Kontovounisios; G Pellino; M Bower; S C Mills; P P Tekkis
Journal:  Tech Coloproctol       Date:  2019-11-20       Impact factor: 3.781

5.  Progression to and spontaneous regression of high-grade anal squamous intraepithelial lesions in HIV-infected and uninfected men.

Authors:  Winnie W Y Tong; Fengyi Jin; Leo C McHugh; Tara Maher; Brett Sinclair; Andrew E Grulich; Richard J Hillman; Andrew Carr
Journal:  AIDS       Date:  2013-09-10       Impact factor: 4.177

6.  International trends in anal cancer incidence rates.

Authors:  Farhad Islami; Jacques Ferlay; Joannie Lortet-Tieulent; Freddie Bray; Ahmedin Jemal
Journal:  Int J Epidemiol       Date:  2017-06-01       Impact factor: 7.196

7.  Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of antiretroviral therapy.

Authors:  Marina T van Leeuwen; Claire M Vajdic; Melanie G Middleton; Ann M McDonald; Matthew Law; John M Kaldor; Andrew E Grulich
Journal:  AIDS       Date:  2009-10-23       Impact factor: 4.177

8.  Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.

Authors:  Roger D James; Robert Glynne-Jones; Helen M Meadows; David Cunningham; Arthur Sun Myint; Mark P Saunders; Timothy Maughan; Alec McDonald; Sharadah Essapen; Martin Leslie; Stephen Falk; Charles Wilson; Simon Gollins; Rubina Begum; Jonathan Ledermann; Latha Kadalayil; David Sebag-Montefiore
Journal:  Lancet Oncol       Date:  2013-04-09       Impact factor: 41.316

9.  The male ScreenING Study: prevalence of HPV-related genital and anal lesions in an urban cohort of HIV-positive men in Germany.

Authors:  W Fuchs; U Wieland; A Skaletz-Rorowski; N H Brockmeyer; J Swoboda; A Kreuter; C Michalik; A Potthoff
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-02-01       Impact factor: 6.166

Review 10.  Evaluating the efficacy of treatment options for anal intraepithelial neoplasia: a systematic review.

Authors:  Danielle R L Brogden; Una Walsh; Gianluca Pellino; Christos Kontovounisios; Paris Tekkis; Sarah C Mills
Journal:  Int J Colorectal Dis       Date:  2020-09-26       Impact factor: 2.796

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.